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Background: Tissue type plasminogen activator is the only approved thrombolytic agent for the treatment of
ischemic stroke. However, it carries the disadvantage of a 10-fold increase in symptomatic and asymptomatic
intracranial hemorrhage. A safer thrombolytic agent may improve patient prognosis and increase patient
participation in thrombolytic treatment. A novel direct-acting thrombolytic agent, Δ(K2-K5) plasmin, promising an
improved safety profile was examined for safety in the snare ligature model of stroke in the rat.
Methods: Male spontaneously hypertensive rats were subjected to 6 hours middle cerebral artery occlusion
followed by 18 hours reflow. Beginning 1 minute before reflow, they were dosed with saline, vehicle, Δ(K2-K5)
plasmin (0.15, 0.5, 1.5, and 5 mg/kg) or recombinant tissue-type plasminogen activator (10 and 30 mg/kg) by local
intra-arterial infusion lasting 10 to 60 minutes. The rats were assessed for bleeding score, infarct volume, modified
Bederson score and general behavioral score. In a parallel study, temporal progression of infarct volume was
determined. In an in vitro study, whole blood clots from humans, canines and rats were exposed to Δ(K2-K5). Clot
lysis was monitored by absorbance at 280 nm.
Results: The main focus of this study was intracranial hemorrhage safety. Δ(K2-K5) plasmin treatment at the highest
dose caused no more intracranial hemorrhage than the lowest dose of recombinant tissue type plasminogen
activator, but showed at least a 5-fold superior safety margin. Secondary results include: temporal infarct volume
progression shows that the greatest expansion of infarct volume occurs within 2–3 hours of middle cerebral artery
occlusion in the spontaneously hypertensive rat. A spike in infarct volume was observed at 6 hours ischemia with
reflow. Δ(K2-K5) plasmin tended to reduce infarct volume and improve behavior compared to controls. In vitro data
suggests that Δ(K2-K5) plasmin is equally effective at lysing clots from humans, canines and rats.
Conclusions: The superior intracranial hemorrhage safety profile of the direct-acting thrombolytic Δ(K2-K5) plasmin
compared with recombinant tissue type plasminogen activator makes this agent a good candidate for clinical
evaluation in the treatment of acute ischemic stroke.
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Recanalization is an effective treatment for acute ische-
mic stroke [1]. Currently, recombinant tissue-type plas-
minogen activator (rt-PA) is the only FDA-approved
pharmacological thrombolytic agent for recanalization
therapy. Although effective, a major drawback of rt-PA
treatment is a 10-fold increase in the risk of symptom-
atic and asymptomatic intracranial hemorrhage (ICH)
[1,2]. A novel thrombolytic agent that effectively lyses
clots while significantly reducing the risk of hemorrhage
may improve overall prognosis and potentially allow
more patients with stroke to be treated.
Recently, a novel recombinant derivative of human plas-
min, Δ(K2-K5) plasmin (TAL6003), was produced in an E.
coli expression system [3]. Δ(K2-K5) plasmin lacks the
middle portion (kringles 2–5) of native plasmin and kringle
1 (K1) is spliced directly to the protease domain. As the K1
domain contains the fibrin and the α2-antiplasmin (α2-AP)
binding sites, Δ(K2-K5) plasmin retains all of the fibrino-
lytic activity as well as the fibrin binding and systemic in-
hibitory characteristics of native plasmin [3,4]. Δ(K2-K5)
plasmin is rapidly neutralized by endogenous inhibitors
after IV administration, accounting for its hemorrhagic
safety profile. However, this attribute requires Δ(K2-K5)
plasmin to be administered by a catheter advanced to the
immediate proximity of the thrombus [5-7]. Δ(K2-K5)
plasmin shows remarkable hemostatic safety in a rabbit fi-
brinolytic hemorrhage model [4,6-8], suggesting that, like
native plasmin, Δ(K2-K5) plasmin poses significantly less
systemic hemorrhagic risk than rt-PA.
In a safety study, a range of test article (compound
under study) dosages spanning the presumptive thera-
peutic dose are selected to determine a No Observable
Adverse Effect Level (NOAEL). From these, a margin of
safety (NOAEL  therapeutic dose) can be calculated. In
this study, a wide dose range of Δ(K2-K5) plasmin (0.15
to 5 mg/kg) spanning the presumptive therapeutic dose
of 1 mg/kg, extrapolated from Marder et al. [9] and
Crumrine et al. [10], was investigated. The FDA approved
thrombolytic agent, rt-PA, was used as an industry stand-
ard for comparison as well as a positive control for ICH
detection in the model system. Previously, we showed
that dosages of rt-PA of less than or equal to 10 mg/kg
delivered intra-arterially (IA) caused no more ICH than
saline; suggesting a margin of safety for rt-PA of approxi-
mately 1 following a 6 hour ischemic insult [11].
Treatment with IV rt-PA is effective when adminis-
tered within 3 hours of stroke onset [1], but this narrow
therapeutic window limits patient eligibility for thrombo-
lytic therapy – estimated at only 1–2% [12]. Recently, the
therapeutic window for IV rt-PA treatment was extended
to 4.5 hours [2,13] and there is an ongoing clinical study
aimed at further extending this window to 6 hours [14].
In light of this, we used a 6 hour ischemic durationin this study to simulate the extended ischemic dur-
ation for patient recruitment in future clinical studies –
being a safety study, we wanted to mimic the “worst case
scenario” for patient studies.
We used the snare ligature model of mechanical middle
cerebral artery occlusion (MCAo) in the spontaneously
hypertensive rat (SHR) [11] to mimic recanalization ther-
apy for this study based on the remarkable consistency of
the SHR in this model system and the necessity to
strictly control the ischemic duration. The latter is not
possible with a thromboembolic model where the onset
of rt-PA treatment can be controlled but the onset of
recanalization cannot. For example, treatment with rt-PA
1 hour after cerebral thrombosis in the rat results in
recanalization 15 to 60 minutes later, making the effect-
ive ischemic duration between 75 and 120 minutes. In
our previous study, we showed that ischemic duration
profoundly affects infarct volume. In a safety study such
as this, uncontrolled recanalization would make the
infarct volume data uninterpretable. This would also be
true for the hemorrhage data as ICH liability increases
with increased ischemic duration [11]. Furthermore,
control groups such as saline and vehicle treatment in
a thromboemoblic model would necessarily reflect
permanent occlusion as neither can lyse a clot. These
complications of a thromboembolic model would prevent
the establishment of a true baseline, leading to distortion
and misinterpretation of the data. In addition, the snare
ligature model of MCAo allowed for the initiation of IA
treatment to immediately precede reflow, better reflecting
thrombolytic treatment in humans. This is not possible in
an intralumenal model as there would be a significant
time delay to replace the occluder with a dosing catheter;
this is in addition to other complications of this model
[15,16]. Although the snare ligature model is somewhat
obscure, it is well characterized; having been used to study
high energy metabolites [17-19], temporal infarct volume
progression [20], protein kinase C activity [21] and in
MRI studies [22].
We used the SHR in our study because of the remark-
able consistency of this strain in stroke studies [11,23].
Furthermore, the strain has a relevant comorbidity for
stroke, hypertension, fulfilling a Stroke Therapy Aca-
demic Industry Roundtable (STAIR) recommendation
for drug development for a stroke indication [24] and
thus may be more relevant for human translational studies
[23]. Additionally, the SHR is resistant to experimental
therapeutic stroke paradigms [25] (personal experience)
with the exception of reflow, very similar to humans.
Finally, an ischemic duration of 6 hours was selected to
simulate an extended interval between stroke symptom
onset to treatment in the clinic.
In summary, as the in vivo thrombolytic efficacy of
Δ(K2-K5) plasmin has been established in large animal











Saline 6 Dose Vol — 1 10 min
Vehicle 6 Dose Vol — 1
rt-PA 5 10 5† 2 20 min
6 30 5† 6 60 min
Δ(K2-K5)
Plasmin
6 0.15 0.3{ 0.5 10 min
6 0.5 0.5 1
6 1.5 1.5 1
5 5 5 1
* BW is the body weight. † this solution was hyperosmotic (792 mOsmol/L).
Solutions of higher concentrations and thus higher osmolality may have
significant physiological effects in ischemic brain tissue. { lower concentrations
of Δ(K2-K5) plasmin may have compromised the integrity of the molecule. The
total volumes infused averaged 0.35 mL, 0.7 mL and 1.95 mL for infusion
durations of 10, 20 and 60 minutes, respectively.
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study was to assess the ICH safety of Δ(K2-K5) plasmin
administered after an extensive cerebral ischemic insult
with recanalization. rt-PA was used as an industry stand-
ard and to validate the ability of the model to detect
ICH. In this report, we established a margin of safety for
rt-PA after 6 hours ischemia with reflow and compared
it to the margin of safety of Δ(K2-K5) plasmin.
Methods
In vitro clot lysis assay
Approximately 87 mg retracted whole venous blood clots
from humans, canines and rats were exposed to 1.14 mg/
mL Δ(K2-K5) plasmin at a 2:1 volume to weight ratio at
room temperature. At designated time points, 5 μL wereFigure 1 Rat snare ligature model. The head of the rat was immobilized
between the eye and external auditory canal. The MCA was exposed by bi
anteriomedial to the juncture of the zygomatic arch with the squamosal b
was isolated from the arachnoid and pia by blunt dissection. Left Panel: co
cerebral artery. Right Panel: removal of the snare ligature resulting in recantransferred into 3 ml of 0.9% NaCl and the degree of clot
lysis was evaluated by increased absorbance at 280 nm
over time. For controls, clots were exposed to equal
volumes of saline.
Animals
Adult male SHRs weighing 330–380 g were obtained
from Charles River Laboratories (Raleigh, NC). Animal
experiments were conducted at North Carolina State
University (NCSU) College of Agriculture and Life
Sciences (CALS). The animal use protocol was reviewed
and approved by the NCSU Institutional Animal Care
and Use Committee prior to the initiation of the study
and was performed in compliance with standards set
forth by the CALS animal facilities.
Upon arrival, the rats were assigned a number by the
animal facility staff and housed individually. They were
allowed at least one week to acclimate. The rats were on
a 12 hour light/dark diurnal cycle with food and water
provided ad libitum. To conserve test article, rats were
assigned to experimental groups in tandem (2 rats to the
same group/experimental day) on a rotating basis as out-
lined in Table 1.
Transient middle cerebral artery occlusion model
Six hours of MCAo was produced in the SHR using the
snare ligature model first described in the mouse [26],
adapted to the rat [11,27] and shown schematically in
Figure 1. Briefly, rats were fasted overnight to obtain
low, stable plasma glucose concentrations. They were
anesthetized with isoflurane (5% in 100% oxygen), oro-
tracheally intubated and administered buprenorphine
(0.03 mg/kg, subcutaneously) for pain relief. A tailin a specially designed head holder. A skin incision was made
secting the temporalis muscle and performing a craniotomy
one. The dura was opened using a tuberculin syringe and the MCA
nstruction of the snare ligature. Middle Panel: occlusion of the middle
alization.
Figure 3 Dosing of thrombolytic agents. For clarity, the
illustration shows a ventral analogy. In practice, once the EC-ICA was
cannulated, the rat was gently rolled onto his right flank and the
injection port was secured to the left flank. The head was, again,
immobilized in the head holder. During this process, patency of the
catheter was maintained by saline infusion (0.75 mL/hr). Infusion of
test article was accomplished by replacing the saline flush syringe
butterfly assembly with an assembly containing the test article. The
infusion of the test article was initiated approximately 1 minute
before dismantling the snare ligature while the head was secured in
the head holder.
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and to obtain arterial blood samples for blood gas ana-
lysis. Following arterial catheterization, artificial ventila-
tion (Model 683 small animal ventilator, Harvard
Apparatus, Natick, MA) was initiated. The isoflurane
anesthetic gas (1.0–1.5 %) was driven by compressed air
supplemented with oxygen to prevent blood hyperoxia.
The head of the rat was immobilized in a specially
designed head holder. A skin incision was made between
the external auditory canal and the eye. The lateral as-
pect of the skull was exposed by cutdown and a small
(~2 mm) craniotomy was performed anteriomedial to
the zygomatic arch. The dura was incised and the mid-
dle cerebral artery was gently dissected from the arach-
noid and pia. A snare ligature device constructed from
10–0 nylon suture, 6–0 prolene suture and a piece of si-
lastic tubing (OD/ID 1.65 mm/0.76 mm; Dow Corning
Corporation) (Figure 1, left panel) was used to occlude
the left MCA (Figure 1, middle panel). Following MCAo,
the rats were recovered from anesthesia, extubated and
returned to a clean cage. The rats had free access to food
(Hydro Gel and Diet Gel-Recovery; ClearH2O, Portland,
ME) during the time interval between placement and re-
moval of the snare ligature.
During surgery, the blood pressure was continuously
recorded electronically using the Ponemah Physiological
Monitoring Platform (DSI, Cleveland, OH). Body
temperature was maintained at or slightly above 37°C
using a heat lamp in a feedback circuit with a rectal
temperature probe (TCAT-2 Temperature Controller,
Physitemp Instruments, Inc., Clifton, NJ). Blood gas
measurements (i-Stat hand-held physiological monitor,
Heska AG, Switzerland) were obtained before MCAo
and adjustments were made if necessary. Surgical sham
animals showed no damage to the brain [11]. For clarity,
a timeline of the study is presented in Figure 2.Experimental groups and dose administration
Table 1 shows the experimental groups and the dosing
characteristics for each group. The IA dosing technique
has been described in detail [11] and is shown in Figure 3.Figure 2 Timeline of the experiment.Briefly, approximately 5 hours after MCAo, the rats were
assessed for neurological function [11,28], re-anesthetized,
intubated and artificially ventilated. The extra-cranial in-
ternal carotid artery (EC-ICA) was catheterized via the ex-
ternal carotid artery (ECA) by cutdown (Figure 3). The
snare ligature was exposed and test article administration
was initiated. Approximately 1 minute later, the snare liga-
ture was dismantled (Figure 1, right panel). The surgical
site was flooded with papaverine to dilate the MCA. Reca-
nalization was confirmed by visual inspection of the artery
through the surgical microscope (Zeiss OPMI-6 C, Pre-
scott’s Inc., Monument, CO). Parallel control experiments
using latex injected into the EC-ICA immediately follow-
ing reflow showed latex filling of the MCA vascular tree
[11] confirming recanalization. Following dosing, the rats
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dose of buprenorphine (0.03 mg/kg, subcutaneously) and
returned to their home cage. EC-ICA dosing shams (dose
volume of saline 6 hours after sham MCAo surgery)
showed no damage to the brain [11].
All 7 dosing solutions (see Table 1) were prepared in
total before beginning the experiment. They were filtered
(0.22 μm filter), dispensed into 1 mL aliquots, snap-
frozen and stored at −80°C. Saline for injection (filtered
and frozen) was used as a control for the vehicle (saline
with 2% trehalose, acidified to pH 3.5 with citric acid).
Five vials of lyophilized rt-PA (Alteplase, Genentech,
Inc., South San Francisco, CA) were solubilized at 5 mg/
mL and pooled before filtering and freezing. rt-PA solu-
tion, stored frozen at −80°C, is stable for at least 7 years
[29]. Due to solubility and osmolality limitations, dosing
concentrations of rt-PA >5 mg/mL were not practical
[11]. The 10 mg/kg dose of rt-PA corresponds to the ef-
ficacious IV dose in rats which is 10-fold higher than in
humans. The discrepancy derives from a 10-fold lower
sensitivity of rat clots to lysis by human rt-PA [30].
Test articles were administered by IA infusion at a rate
of 0.033–0.040 mL/min (except for the 0.15 mg/kg
Δ(K2-K5 plasmin group; see Table 1).
Bleeding score
Twenty four hours after MCAo onset, the rats were deeply
anesthetized with isoflurane (5% in O2). The brains were
perfused transcardially with heparinzed saline (10 U/mL),
removed from the calvarium and immersed in ice cold sa-
line. Digital photographs of the gross brain were obtained.
Sequential 2 mm coronal sections were obtained
throughout the neocortex (8–9 sections/brain). The sec-
tions were stained with 1–2% 2, 3, 5 triphenyl tetrazo-
lium chloride (TTC) [11,31], digitally photographed with
a ruled standard and fixed in 10 % buffered formalin.
Two 10 μm hematoxylin and eosin (H&E) stained sec-
tions, spaced 250 μm apart, were obtained from each ori-
ginal 2 mm TTC stained section (16–18; 10 μm sections/
rat brain) and evaluated for bleeding (Bleeding Score)
using a 7 category scoring system: 0 =Non hemorrhagic
ischemic infarction, 1 =Dispersed individual petechiae,
2 =Confluent petechiae, 3 =Hemorrhagic infarction,
4 = Parenchymal hemorrhage extending beyond the in-
farction, 5 =Death before planned termination due to
parenchymal hemorrhage, 5.5 =Hemorrhage in non-
ischemic brain tissue (for examples of the Bleeding Score,
see Crumrine et al. [11]). The brains were evaluated in
half score increments. The overall score for the rat brain
was the highest score of the evaluated sections.
Bleeding Score was determined in a blinded fashion by
CPT in the laboratory of JCL, Department of Physiology
and Biophysics, Case Western Reserve University, Cleve-
land, Ohio.Infarct volume analysis
The digital photographs of the fresh TTC stained brain
sections were sent to JCL’s laboratory at Case Western
Reserve University in Cleveland, OH. CPT imported each
photograph into an image analysis program (Image-Pro
Plus v4.5, Media Cybernetics, Inc., Bethesda, MD). The
infarct volume, reported in mm3, was determined by the
indirect method in a blinded manner by CPT.Neurological function analysis (modified Bederson score)
The rats were assessed for neurological function twice
during the study – once prior to the induction of
anesthesia to place the EC-ICA catheter for test article
administration and again just before euthanasia. The first
assessment was used to screen for stroke presence. Any
rat not displaying a score of at least 2 was eliminated
from the study. The second score was analyzed as an ex-
perimental variable.
A modified Bederson score [11,28] was used with the
following definitions: Score 0: No apparent neurological
deficits; Score 1: Body torsion present; Score 2: Body tor-
sion with right side weakness; Score 3: Body torsion,
right side weakness with circling behavior; Score 4: Seiz-
ure Activity.
The score was assessed in a non-blinded manner by
Grifols Therapeutics, Inc. personnel (RCC or GMT).General behavioral score
In addition to the neurological score, a general behav-
ioral score was developed. The score was used to assess
the general alertness and responsiveness of the rats 24
hours after MCAo; behaviors not captured in the modi-
fied Bederson score. The score had the following defini-
tions: Score 0: Behavior consistent with a normal naïve
rat (i.e. no ipsilateral deficit); Score 1: Bright/active/re-
sponsive; the rat spontaneously moves and explores his
cage, responds to external stimuli, explores the top of
the cage; Score 2: Quiet/alert/responsive; reserved be-
havior but will respond to external stimulus, tends not
to rear or explore the top of the cage; Score 3: Depressed
behavior: tends not to move unless prodded, quickly
returns to a somnolent state, little to no interest in ex-
ternal stimuli; Score 4: Unresponsive: remains in a pros-
trate position even when prodded; Score 5: Seizure
activity requiring euthanasia.
The behavioral categories were developed by the CALS
personal for the purpose of monitoring recovery of ani-
mals following surgical procedures (standard CALS
post-operative care). A numerical value was assigned to
the predetermined behavioral observations. The rats
were scored by the same person (BJW) from CALS in a
blinded manner.
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Animals were excluded from the study for the following
reasons: breakage of the MCA during occlusion or reca-
nalization; breakage of a side branch of the MCA caus-
ing bleeding at the surgical site; lack of right side
weakness; occlusion device failure; reflow could not be
visually confirmed; bruising of the brain during the oc-
clusion surgery; air bubbles or particles in the ICA cath-
eter during infusions; surgical complications requiring
euthanasia, evidence of bleeding upon reopening of the
surgical site, plasma glucose concentration >11.5 mmol/
L prior to MCAo.
Statistics
Analysis of the infarct volume and physiological vari-
ables between the experimental groups was accom-
plished by ANOVA followed by Tukey-Kramer HSD
multiple comparison test (JMP statistical software, SAS
Institute, Inc., Cary, NC).
Statistical analysis of the modified Bederson score and
the general behavioral score was accomplished using the
Kruskal-Wallis one way ANOVA followed by Newman-
Keuls multiple comparisons test for non-parametric data
using the GBstat statistical package (Dynamic Microsys-
tems, Inc., Silver Spring, MD).
To estimate the number of animals per group, a power
analysis was performed on the vehicle group from a con-
temporary pilot study using infarct volume as the test
variable. To observe a statistically significant difference
of 30% between means of the experimental groups at an
α level of 0.05 and a β level of 0.8, a minimum of 5 ani-
mals would be required (personal observation). This is
consistent with Brint et al. [23] and with our past experi-
ence using the SHR in this model system.
Results
In vitro thrombolysis
No change in absorbance at 280 nm was observed
when retracted whole blood clots were exposed to ve-
hicle (Figure 4). Clots from humans, canines and rats
showed nearly identical lysis kinetics when exposed to
Δ(K2-K5) plasmin (Figure 4).
Exclusion of animals and physiological variables
Forty eight rats were assigned to the experimental
groups. Ten were excluded from the study based on the
a priori exclusion criteria including: breakage of the
MCA (2), excessive surgical bleeding (3), lack of right
side weakness (1), missing brain sections (2), high pre-
ischemia plasma glucose concentration (1), and non-
recovery from anesthesia (1).
The physiological variables prior to MCAo, prior
to reflow and just after completion of test article in-
fusion are presented in Additional file 1 (Tables S1,Additional file 1: S2, and Additional file 1: S3). All of the
variables were within physiological range. There was a
marked increase in the plasma glucose concentrations prior
to reflow which reflect the rats having free access to food
between the two procedures (comparison of glucose values
in Table S1 and S2). There was a significant increase in the
pulse pressure following infusion of 10 and 30 mg/kg
of rt-PA as compared to the pre-reflow values (TAL6003-
Suppl-RCC; comparison of values in Table S2 and S3).
Intracranial hemorrhage
Photographs of the gross brain and representative TTC
stained 2 mm sections from rats treated with vehicle, 10
and 30 mg/kg rt-PA and 5 mg/kg Δ(K2-K5) plasmin are
shown in Figures 5, 6, 7, and 8. Vehicle treated rats had
some superficial bleeding in the gross brain (Figure 5A)
but the TTC stained sections are mostly hemorrhage
free. However, there was evidence of small areas of pe-
techial hemorrhages in rats 63499 and 63855 (Figure 5B,
small blue arrows) which was confirmed by histological
evaluation. Rats treated with 10 mg/kg rt-PA showed
more bleeding on the brain surface compared to vehicle
especially for rat 63853 where blood covered a large por-
tion of the ipsilateral hemisphere (Figure 6A) portending
a large parenchymal hemorrhage in the TTC stained sec-
tion (Figure 6B, large blue arrow). Two animals showed
smaller hemorrhagic infarcts (Figure 6B; rats 62556, 63485,
large blue arrows) and two others showed evidence of
petechial hemorrhage (Figure 6B, small arrows). There
were no deaths or premature euthanasia.
Increasing the dose of rt-PA to 30 mg/kg resulted in
more severe bleeding (Figure 7). Exclusive to this group
was hemorrhage in the brain stem in 3 of 6 rats (Figure 7A
and B; rats 62565, 64575, 63856, large black arrows). In two
of these (rats 63856, 64575), bleeding in the brain stem was
associated with hypothalamic damage and seizure activity,
requiring premature euthanasia while the third (62565) had
bleeding in the pons area (Figure 7B; large black arrows).
Three rats had evidence of hemorrhagic infarction (62559,
62565, 63856; Figure 7B, large blue arrows), one rat showed
extensive petechial hemorrhage (62560) and one rat had a
seemingly clean infarct (63482). These observations were
similar to those noted in a previous study using rt-PA in
this model system [11].
Treatment with the highest dose of Δ(K2-K5) plasmin
(5 mg/kg) resulted in little to moderate superficial bleed-
ing (Figure 8A). There was evidence of petechial bleeding
in three rats (Figure 8B, small blue arrows) and 2 rats
appeared to have clean infarcts.
The Bleeding Score based on histological evaluation
of H&E sections as well as gross observations for the
groups are presented in Figure 9 (graphed data are
presented in Additional file 1, Table S4). Rats treated
with saline or vehicle had minimal bleeding. Rats
Figure 4 Clot lysis kinetics of Δ(K2-K5) plasmin. Retracted whole blood clots (87 mg) from humans, canines and rats were exposed to
1.14 mg/mL Δ(K2-K5) plasmin in vitro. At the indicated time points, samples were assayed for optical density at 280 nm.
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bleeding than both the saline and vehicle groups. In-
creasing the dose of rt-PA to 30 mg/kg increased
bleeding severity although not to the level of statistical
significance compared to the 10 mg/kg rt-PA group
(Figure 9).Figure 5 Photographs of the brains from the vehicle group. A) Photog
Sections from each rat. Small blue arrows indicate areas of petechial hemoThe Bleeding Scores for all 4 Δ(K2-K5) plasmin treat-
ment groups (Figure 9) were low and similar to those
animals treated with saline or vehicle (compare Figure 5
with Figure. 8). On the contrary, the scores for both rt-
PA groups were higher than in animals receiving control
infusions.raphs of the gross brain of each rat. B) Representative TTC Stained
rrhage.
Figure 6 Brain photographs from the 10 mg/kg rt-PA group. A) Photographs of the gross brain of each rat. B) Representative TTC Stained
Sections from each rat. Small blue arrows indicate areas of petechial hemorrhage. Large blue arrows indicate hemorrhagic infarction.
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have lower Bleeding Scores than the 10 mg/kg rt-PA
group, these differences failed to reach the level of statis-
tical significance. All four Δ(K2-K5) plasmin treated
groups had significantly less bleeding compared to the
30 mg/kg rt-PA treated group. There was no evidence of
increased bleeding severity with increasing dose of
Δ(K2-K5) plasmin (Figure 9).Infarct volume
The temporal progression of infarct volume development
for the SHR in our model is presented in Figure 10. Rats
were subjected to 1, 1.5, 2, 4, 6 and 24 hours (permanent)
MCAo followed by reflow. All rats were euthanized 24
hours after onset of MCAo. As the ischemic duration
was increased from 1 (infarct volume 12 ± 7 mm3) to 4
(infarct volume 171 ± 17 mm3) hours, there was a pro-
gressive increase in infarct volume which was particularly
noticeable between 1.5 (55 ± 6 mm3) and 2 hours MCAo
(158 ± 13 mm3); a Δ change of 103 mm3. The infarct vol-
ume after 2 and 4 hours MCAo was similar to permanent
occlusion (166 ± 10 mm3) of the MCA. Increasing the
ischemic duration to 6 hours (261 ± 20 mm3) resulted in
significantly larger infarcts than all other groups.
Sham animals did not have any observable damage to the
brain [11].The contralateral/ipsilateral hemisphere ratio (indica-
tive of brain swelling) for the 1 hour group was nearly
identical to that of the sham animals (0.98 ± 0.02). Ani-
mals subjected to 6 hours of MCAo with reflow had
greater cerebral swelling than did all other ischemic
durations. Animals subjected to 1 hour ischemia had less
edema than rats with permanent MCAo (Figure 10).
The infarct volumes for the experimental groups in
the MCAo safety study are presented in Figure 11. Due
to the ischemic duration and the use of the SHR, the
scatter plot of the individual animals reveals the remark-
able consistency of the infarct data.
The study consisted of 4 control groups. The saline
group was a control for the vehicle group. The vehicle
group was a control for the Δ(K2-K5) plasmin groups.
Both of the rt-PA groups acted as positive controls. The
infarct volumes were consistent over the 4 control
groups (269 ± 18 mm3, 240 ± 17 mm3, 255 ± 13 mm3, and
258 ± 11 mm3, for saline, vehicle and 10 and 30 mg/kg
rt-PA groups, respectively). Statistically they were the
same (p> 0.95; saline vs. vehicle, p = 0.9043). Rats trea-
ted with Δ(K2-K5) plasmin tended to have smaller in-
farct volumes compared to controls. Rats treated with
0.15 mg/kg Δ(K2-K5) plasmin had a significantly smaller
infarct volume (194 ± 18 mm3) compared to saline
(p = 0.0449). There was a trend (not statistically signifi-
cant) for a progressive reduction in infarct volume with
Figure 7 Brain photographs from the 30 mg/kg rt-PA group. A) Photographs of the gross brain of each rat. B) Representative TTC Stained
Sections from each rat. Small blue arrows indicate areas of petechial hemorrhage. Large blue arrows indicate hemorrhagic infarction. Large black
arrows indicate hemorrhage to the brain stem (A) or damage to the hypothalamus or pons (B).
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to 1.5 mg/kg (221 ± 22 mm3) to 5 mg/kg (197 ± 12 mm3)
(Figure 11).
Modified Bederson score
The modified Bederson score data are presented in
Figure 12 (graphed data are presented in Additional
file 1, Table S5). The 30 mg/kg rt-PA group had a sig-
nificantly worse functional outcome compared to all of
the other groups in the study. Rats treated with Δ(K2-
K5) plasmin were not significantly different from those
receiving saline or vehicle groups.
Behavioral score
The general behavioral score data are presented in
Figure 13 (graphed data presented in Additional file 1,
Table S6). Rats treated with saline, vehicle or 10 mg/kg
rt-PA were active and alert after 18 hours of recovery.
Rats treated with 30 mg/kg rt-PA were very lethargiccharacterized by lack of spontaneous movement. In gen-
eral, rats receiving Δ(K2-K5) plasmin were more alert
and active than rats treated with saline, vehicle or rt-PA.
Rats dosed with 5 mg/kg Δ(K2-K5) plasmin were signifi-
cantly more alert and active than saline controls.
Discussion
As in vivo thrombolytic efficacy has been previously estab-
lished, the primary focus of this study was to determine the
ICH safety liability of the novel direct acting thrombolytic
agent Δ(K2-K5) plasmin following an extended ischemic in-
sult in a model of focal cerebral ischemia in the rat. An is-
chemic duration of 6 hours was selected to better mimic
extended symptom onset to treatment in the clinic and to
simulate a “worst case scenario” common in safety studies.
The main finding of the study was that high dose Δ(K2-K5)
plasmin treatment was statistically no worse than low dose
rt-PA at causing ICH but had a greater margin of safety.
Surprisingly, secondary observations suggested that Δ(K2-
Figure 8 Brain photographs from the 5 mg/kg Δ(K2-K5) plasmin group. A) Photographs of the gross brain of each rat. B) Representative
TTC Stained Sections from each rat. Small blue arrows indicate areas of petechial hemorrhage.
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ume and significantly improve behavior.
In vitro efficacy and dose considerations
Our in vitro data (Figure 4) suggests that Δ(K2-K5) plas-
min would have equal thrombolytic efficacy in rats,Figure 9 Box-Whisker Plot of the Bleeding Score. * p< 0.05 for the ind
comparison test for non-parametric data; n = 6, 6, 5, 6, 6, 6, 6, 5, respectivelcanines, and humans. Indeed, on an equal molar basis,
native plasmin/Δ(K2-K5) plasmin demonstrates similar
lysis kinetics for clots derived from a host of species in-
cluding humans, canines, rabbits, rats, bovine, and ovine
[3,4,32]. This is in contrast to rt-PA where a 10-fold
greater dosage is required for rat vs. humanicated groups (Kruskal-Wallis ANOVA, Newman-Keuls multiple
y). Values are the median± the 5 and 95 percentile.
Figure 10 Temporal progression of the infarct volume. Rats were exposed to the designated duration of MCAo. All rats were euthanized 24
hours after MCAo onset to allow the infarct to mature. Statistics: Groups with like letters are not significantly different (p< 0.05; ANOVA, Tukey-
Kramer HSD). Group values are the mean± SEM.
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http://www.etsmjournal.com/content/4/1/10thrombolysis. This likely reflects the difference in the
mechanism of action between the two molecules. Δ(K2-
K5) plasmin acts directly on clot fibrin whereas rt-PA
requires the intermediate step of conversion of plas-
minogen to plasmin. Rat plasminogen appears to be a
10-fold less sensitive substrate for human rt-PA. Re-
cently, Haeloewyn et al., [33] challenged this conclusion,
suggesting that 0.9 mg/kg rt-PA is equally as effective as
10 mg/kg in the rat when treatment was started 45 min-
utes post MCA thrombosis. Inspection of the data shows
that 0.9 mg/kg rt-PA resulted in a significant delay toFigure 11 Scatter plot of the infarct volume of the experimental grou
followed by 18 hours reflow. Test articles were infused IA over 10 to 60 mi
groups (ANOVA, Tukey Kramer HSD; n = 6, 6, 5, 6, 6, 6, 6, 5, respectively). Grreflow, significantly reduced cumulative reperfusion, a
near doubling in the infarct volume and a near tripling
in edema volume compared to 10 mg/kg rt-PA treated
animals. The reason the latter two variables were not
statistically significantly different between the two
groups was due to the large variability in the 10 mg/kg
rt-PA group. Wang et al., [34] showed that treatment
with 5 mg/kg rt-PA beginning 1 hour following MCA
thrombosis in the rat did not reduce infarct volume
compared to control whereas 10 mg/kg rt-PA did. Taken
together, 10 mg/kg rt-PA is clearly more therapeutic inps. Rats were subjected to 6 hours middle cerebral artery occlusion
nutes beginning 1 minute before reflow. * p< 0.05 for the indicated
oup values are the mean± SEM.
Figure 12 Modified Bederson score. Rats were exposed to 6 hours middle cerebral artery occlusion followed by 18 hours reflow. Test articles
were infused IA over 10 to 60 minutes beginning 1 minute before reflow . * p< 0.05 compared to all other groups (Kruskal-Wallis, Newman-Keuls;
n = 6, 6, 5, 6, 6, 6, 6, 5, respectively). Values are the median ± the 5 and 95 percentile.
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the rate of clot lysis following thrombolytic treatment is
crucial for improved outcome. This is because the rate
of thrombolysis determines the overall ischemic insult
and is related to the local concentration of the thrombo-
lytic agent which in turn is related to the dose. This
reflects clinical experience where early recanalization is
correlated with improved outcome [35,36].
The in vivo thrombolytic efficacy of Δ(K2-K5) plasmin
was established in rabbit and canine thrombosis modelsFigure 13 General behavioral score. * p< 0.05 compared to all other gr
(Kruskal-Wallis, Newman-Keuls; n = 6, 6, 5, 6, 6, 6, 6, 5, respectively). Values abecause larger animals better accommodated the dosing
requirements of direct acting thrombolytic agents. In a
rabbit model of MCA thrombosis, 0.25 to 1 mg/kg na-
tive plasmin lysed the thrombus and restored blood flow
to the brain [9]. The molecular weight of Δ(K2-K5) plas-
min is approximately half that of native plasmin (37000
vs. 81000, respectively) and because the catalytic proper-
ties of native and Δ(K2-K5) plasmin are identical [3,4],
on a molar to molar basis, the analogous dose for Δ(K2-
K5) plasmin would be 0.114 to 0.5 mg/kg. Thisoups; † p< 0.05 compared to vehicle; {p< 0.05 compared to saline
re the median ± the 5 and 95 percentile.
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this same model system (Marder, personal communica-
tion). In a Beagle dog model of femoral artery throm-
bosis (artery diameter similar to human MCA), the
thrombolytic efficacious dose for Δ(K2-K5) plasmin was
approximately 1 mg/kg [10]. These data, coupled conser-
vatively with our in vitro data showing equal lytic activ-
ity on clots derived from rats, canines and humans
(Figure 4), support a thrombolytic efficacious dose of
1 mg/kg Δ(K2-K5) plasmin in the rat.
Intracerebral hemorrhage – safety
In a safety study, escalating doses of test article are used
to establish a margin of safety by relating the efficacious
dose to the NOAEL dose (margin of safety =NOAEL 
efficacious dose). In this study, the NOAEL dose was
defined as the dose at which ICH was no greater than
saline and vehicle. We used rt-PA as an ICH positive
control. The 30 mg/kg rt-PA dose was clearly toxic and
so confirmed that the 10 mg/kg dose, the therapeutic
dose in rats, was near the NOAEL dose. Thus, a conser-
vative estimate of the margin of safety for rt-PA at 6
hours cerebral ischemia in the rat is equal to 10 mg/kg
(NOAEL dose)  10 mg/kg (Efficacious dose), or 1.
However, because 10 mg/kg rt-PA caused significantly
more bleeding than saline and vehicle, the margin of
safety, in reality, is less than 1. This result is similar to
that observed in an IA dose escalation study using rt-PA
(1, 5, 10 and 30 mg/kg) under the same conditions
described here [11]. In that study, IA doses of rt-PA less
than 10 mg/kg did not result in greater ICH compared
to saline; indicating that 10 mg/kg is the highest no ICH
effect dose [11]. In contrast, the presumptive thrombo-
lytic efficacious dose for Δ(K2-K5) plasmin is 1 mg/kg
based on cerebral thrombolysis studies in the rabbit [9]
(Marder, personal communication) and a femoral artery
thrombolysis study in the dog [10]. In this investigation,
no increase in ICH over control was observed even at
doses 5 times greater than the presumptive efficacious
dose (5 mg/kg; highest dose tested); indicating a margin
of safety of greater than 5. Therefore, Δ(K2-K5) plasmin
demonstrates at least a 5-fold greater safety margin than
rt-PA following an extended ischemic insult in the rat.
Ischemia predisposes the cerebral vasculature and par-
enchyma to bleeding complications following reflow, es-
pecially after an extended ischemic event [37]. High
concentrations of thrombolytic agents delivered by local
IA infusion in the first pass of blood following recanali-
zation may be particularly damaging due to the lack of
systemic dilution of the thrombolytic agent. Considering
this, we closely mimicked such conditions by use of a
snare ligature model, which enabled us to initiate IA rt-
PA and Δ(K2-K5) plasmin immediately prior to vascular
recanalization. Furthermore, as fibrin degradationproducts may contribute to thrombolytic-associated is-
chemic damage [38,39], the snare ligature model allowed
us to dissociate hemorrhagic damage caused by rt-PA or
Δ(K2-K5) plasmin from that caused by degradation pro-
ducts. Thus, the effects on bleeding were intrinsic to the
test articles and not a secondary phenomenon. Δ(K2-K5)
plasmin even at high dosages infused IA did not result
in more severe ICH than saline or vehicle treated ani-
mals. This suggests that Δ(K2-K5) plasmin, at the doses
used here, did not show an intrinsic tendency to increase
ICH, whereas even the lowest dose (accepted thrombo-
lytic therapeutic dose in the rat) of rt-PA did. In
addition, there was no evidence of increased bleeding
with increasing doses of Δ(K2-K5) plasmin suggesting
toxic dosages with respect to bleeding were not reached.
IA administration of rt-PA may be a more effective
route for thrombolysis than IV and thus, less drug may
be needed [40]. When 10 mg/kg rt-PA was administered
to rats IA following 3 hours thromboembolic stroke,
there was reduced infarct volume and MRI indicators of
damage were improved over the same dose IV without a
concomitant increase in ICH [41]. The authors could
have titrated the IA dose to match the infarct volume of
IV dose but that would have been counterproductive.
These data suggest that 10 mg/kg rt-PA IA or IV in the
rat is the effective dose. In the clinic, for IA dosing of rt-
PA, the total IV dose is typically split; two thirds IV fol-
lowed by one third IA. Thus the patient receives the
complete IV dose even with IA administration. Indeed,
there is a current push to administer the complete IV
dose of rt-PA and then to supplement with additional rt-
PA IA, resulting in an overall dose exceeding the current
ceiling of 0.9 mg/kg [42]. This may lead to even greater
ICH risk to the patient and may call for severe restric-
tion of patient selection for this treatment paradigm.
IA rt-PA administration, though more effective in lys-
ing a large thrombus in the M1 segment, results in
increased risk of ICH compared to IV treatment alone,
thereby confirming the extremely narrow safety margin
of rt-PA. Furthermore, overdose of rt-PA in the clinic
may be more prevalent than previously thought as physi-
cians tend to overestimate the body weight of stroke
patients [43]. Δ(K2-K5) plasmin, as an add on to rt-PA
treatment or as a stand-alone therapy has the potential
to circumvent these complications.
Infarct volume
Similar to our previous study [11] and consistent with
the literature [44,45], the greatest expansion of infarct
volume in the SHR occurs within the first 2–3 hours
of MCAo, observed in mechanical [11,44] as well as
thromboembolic models [45]. The infarct volumes at 2
and 4 hours and in permanently occluded animals are
nearly the same suggesting an asymptote effect.
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crease in infarct volume following reflow after 6 hours
MCAo. The cause of the spike in infarct volume is un-
clear but may be related to a significant increase in
brain edema. The contralateral to ipsilateral hemi-
sphere ratio was markedly and significantly reduced
after 6 hours MCAo/reflow group compared to all
other groups. Ischemia predisposes the blood brain
barrier to breakdown leading to an increase in vaso-
genic edema, especially after an extended ischemic
event. Permanent MCAo caused a significant increase
in edema compared to sham and 1 hour ischemia. Re-
turn of blood flow to areas of severe blood brain bar-
rier damage would augment edema formation and
thus, may aggravate cerebral infarction.
Our study included 4 control groups: saline, vehicle,
and the two rt-PA groups. Statistical analysis comparing
these groups suggests that they are statistically signifi-
cantly the same (i.e. p> 0.95; saline group vs. vehicle
group >0.9); reflecting the remarkable consistency of
the SHR in this model system, similar to that reported
in the literature [23] as well as in our previous study
[11]. Considering this consistency, it would not be un-
reasonable to merge the data from these 4 groups and
likewise to do the same with the data from animals trea-
ted with Δ(K2-K5) plasmin (consistent with clinical
studies [46]). The infarct volume of the resulting control
group is 255.3 ± 7.4 (mean ± SEM, n = 23) while that of
the resulting Δ(K2-K5) plasmin group is 211.9 ± 9.4
(mean ± SEM, n = 22). Statistical analysis of these two
groups is highly significant (p< 0.001, Students t-test).
This result was unexpected – due to the extended ische-
mic duration, the infarct volumes of all of the groups
were expected to be very similar.
The FDA-approved indirect-acting thrombolytic agent,
rt-PA, is an effective means of achieving recanalization
therapy. Our temporal data clearly shows that recanali-
zation beyond 2–3 hours is non-therapeutic and thus,
rt-PA at any dose past 3 hours post-ictus should not re-
duce infarct volume in our model system. A priori, there
was no expectation of infarct volume reduction for any
treatment especially for a thrombolytic agent including
Δ(K2-K5) plasmin. Indeed, expansion of cerebral dam-
age, especially after a 6 hour ischemic insult, with high
dose rt-PA treatment was more probable and antici-
pated. Considering the ischemic duration and the use of
the SHR, the observed trend for reduction of infarct vol-
ume with Δ(K2-K5) plasmin treatment was remarkable.
The reason for the potential improvement in infarct
volume is not clear. However, depleting the circulating
plasma concentration of α2-AP by use of antibodies,
plasmin or microplasmin in permanent cerebral ische-
mia has been shown to reduce infarct volume [47] and/
or improve behavior [48]. As Δ(K2-K5) plasmin notbound to fibrin would bind and remove α2-AP from the
systemic circulation, it also may have neuroprotective
properties. On a molar basis, the doses of Δ(K2-K5)
plasmin used in our study are within the putative neuro-
protection range. Further, because of its smaller size and
lack of a requirement for plasminogen, Δ(K2-K5) plas-
min may be better than rt-PA at lysing microclots that
may become lodged in the periphery of the penumbra
thereby improving regional blood flow. These two possi-
bilities may explain the remarkable behavioral recovery
of Δ(K2-K5) plasmin treated rats as well as the tendency
for reduced infarct volume.Behavioral observations
The modified Bederson score is a rough estimate of the
functional recovery of the rat and is not sensitive to
subtleties. To obtain a better overall judgment of the
rats’ recovery, we analyzed the clinical evaluation of the
animals examined 2 hours before euthanasia (22 hours
post MCAo onset) by a member of the CALS staff
(BJW) who had no knowledge of the treatment of the
rats. Indeed, the score is simply a numerical value ap-
plied to categories already defined by the CALS staff as
part of the standard care for animals recovering from
surgery. The majority of the animals treated with Δ(K2-
K5) plasmin showed significantly greater activity and
alertness than the control or rt-PA treated rats. This
improved behavior may be an intrinsic property of
Δ(K2-K5) plasmin or it may reflect the tendency of
Δ(K2-K5) plasmin treatment to reduce infarct volume
and to not aggravate ICH. Future studies are needed to
better define this observation.Model selection
Selection of the snare ligature model allowed us to
strictly control the timing of reflow, leading to less vari-
ability in the infarct volume data. This is not possible
with a thromboembolic model, where the initiation of
thrombolytic treatment can be controlled but the timing
of recanalization cannot. Our data suggests that an
interval as short as 30 minutes can have marked effects
on the size of the infarct volume, especially in the early
(<4 hours) ischemia time window. Further, in a
thromboembolic model, the saline and vehicle control
groups would necessarily reflect permanent ischemia
and thus no real baseline would be set for test article
treatment comparison which may lead to misinterpret-
ation of the data. This is confirmed by our data (Figure 5)
showing a significant increase in infarct volume at 6
hours ischemia with reflow compared to the perman-
ently occluded group. Thus, using a thromboembolic
model, the control infarct volume used to compare the
treatment groups would be 166 ± 10 mm3 which would
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K5) plasmin treatment increased infarct volume.
In addition, the snare ligature model allows for the
initiation of local IA administration of test article to
immediately precede reflow – this is not possible
using an intraluminal model where a significant time
delay must occur in order to exchange the occluder
for the dosing catheter. This is in addition to other
complications associated with the intraluminal model
such as premature reflow [15], ischemia to the hypo-
thalamus resulting in hyperthermia [16], distension of
the MCA (personal observations) and filament related
subarachnoid hemorrhage [15].
Conclusions
The purpose of this study was to assess the ICH safety
of the novel direct acting thrombolyic, Δ(K2-K5) plas-
min, as a prelude to clinical studies. Even at the highest
dose administered, Δ(K2-K5) plasmin caused no worse
ICH than the lowest dose of rt-PA but demonstrated at
least a 5-fold greater safety margin than rt-PA – poten-
tially making Δ(K2-K5) plasmin a better selection for
add-on thrombolytic therapy with rt-PA, or as a stand-
alone thrombolytic treatment. Surprisingly, Δ(K2-K5)
plasmin showed potential as a neuroprotective agent by
virtue of its tendency to reduce infarct volume and im-
prove behavior. Future studies will be required to assess
the full potential of Δ(K2-K5) plasmin in stroke.
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Table S2. Pre-reflow physiological variables, Table S3. 5 minutes
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figure 9, Table S5. Data graphed in figure 12, Table S6. Data
graphed in figure 13.
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